You are here: Industry Insights > DKN-01

News List

Leap Therapeutics announces orphan drug designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer pharmaceutical-business-review
June 17, 2020
Leap Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer.
BeiGene obtains certain rights for Leap Therapeutics’ cancer drug pharmaceutical-technology
January 07, 2020
Chinese biopharmaceutical firm BeiGene has agreed to exclusive rights to develop and commercialise Leap Therapeutics’ cancer drug DKN-01 in the Asia Pacific region, excluding Japan.
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing firstwordpharma
January 05, 2020
Raymond James & Associates, Inc. was the placement agent for the equity financing.
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 americanpharmaceuticalreview
January 15, 2019
Leap Therapeutics announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01......